Peptides in 2TM · Liraglutide
Episode 02 · 2 minutes · English
Liraglutide: making the signal last
A short-lived hormone, a Danish discovery team, and a design that extended the signal. Explore liraglutide’s development, albumin binding, and the distinction between Victoza and Saxenda.
English narration and captions. Caption timing is approximate. Translated subtitles are not yet available for this episode.
Published .
Behind the film: Liraglutide references & context
Explore the research, discovery history, prescribing information, and visual sources behind Episode 2. Source verification is distinct from scientific assessment or personal human review; listing these sources does not imply endorsement.
Native GLP-1’s roughly 1–2 minute plasma half-life is distinct from liraglutide’s approximately 13-hour half-life after subcutaneous administration. Liraglutide’s prolonged profile involves delayed absorption, protein binding, and resistance to enzymatic breakdown; albumin binding is not its only cause.
The film’s thyroid restriction refers to personal or family history of medullary thyroid carcinoma or MEN 2 under U.S. labeling, not every thyroid condition. The film presents selected safety information, not complete prescribing guidance. Approval, indications, and availability vary by country.
- Knudsen & Lau, Frontiers in Endocrinology, 2019: discovery and development of liraglutide and semaglutide. Company-authored review; employment and share ownership at Novo Nordisk disclosed.
- Victoza U.S. prescribing information: mechanism, pharmacokinetics, and safety.
- EMA: Victoza and EMA: Saxenda: EU authorization and product information.
- Lasker Foundation: GLP-1 discovery history.
Production: synthetic narration and music; AI-generated conceptual molecular and pharmaceutical scenes. These do not show validated molecular structures or actual manufacturing facilities. No independent human scientific review is claimed.
Real microscopy: “Inner surface of ileum,” Prof Giorgio Gabella / Wellcome Collection, CC BY 4.0; cropped, resized, shaded, and placed in the WPF layout. This shows intestinal villi, not individual GLP-1 molecules or hormone secretion.
Headquarters photograph: News Øresund / Johan Wessman, Novo Nordisk headquarters, Bagsværd, 2016, CC BY 3.0; cropped, shaded, animated, and overlaid with text. This is not the historical discovery laboratory.
Educational information, not medical advice. WPF does not sell peptides. Sources support the film’s context; their inclusion does not imply endorsement. Suggest a correction.
Read the English transcript — Liraglutide
How do you turn a signal that disappears within minutes into a medicine that lasts through the day? This is liraglutide.
After a meal, your intestine releases GLP-1, a hormone that helps coordinate blood sugar and appetite. But the natural hormone is rapidly broken down.
In Denmark, Lotte Bjerre Knudsen and colleagues at Novo Nordisk helped solve that problem. Building on earlier discoveries, their team explored ways to extend the signal without losing its activity.
Their design attached a fatty-acid chain to a modified GLP-1 peptide. This allowed liraglutide to bind reversibly to albumin, an abundant blood protein, helping it remain in the body longer.
After injection beneath the skin, liraglutide is gradually absorbed into circulation. Albumin binding is temporary: the unbound medicine can activate GLP-1 receptors.
In the pancreas, that signaling helps release insulin when blood glucose is elevated and reduces glucagon secretion. Liraglutide also slows stomach emptying and influences pathways involved in appetite.
Victoza received European Union authorization in 2009 and U.S. approval in 2010 for type 2 diabetes. Liraglutide later reached weight-management treatment as Saxenda.
The active ingredient is the same, but the products have different prescribing requirements. Approval and availability vary by country.
Benefits come with limitations. Nausea and vomiting are common; serious warnings include pancreatitis, gallbladder problems, and restrictions related to certain thyroid conditions.
Liraglutide helped establish a foundation for later, longer-acting medicines.
Explore the history and evidence at World Peptide Foundation. This is Peptides in 2. Every experience matters.